A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
Efficacy and Safety Assessment of T1695 Ophthalmic Suspension, Versus Ciclosporin Ophthalmic Emulsion, in Participants With Moderate to Severe Vernal Keratoconjunctivitis (VKC)
Laboratoires Thea
120 participants
Mar 24, 2026
INTERVENTIONAL
Conditions
Summary
The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis
Eligibility
Inclusion Criteria3
- Informed consent signed and dated
- Male or female participant from 4 years to less than 18 years old.
- Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.
Exclusion Criteria1
- Participants must not have any conditions which might exclude them from participating, could interfere with the study, or pose an unacceptable risk to their health.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The participant will have a slit lamp examination
The participant 's BCVA will be evaluated.
The participant should instill T1695.
The participant should instill Ciclosporin.
One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07169695